

American Society of Hematology Annual Meeting (ASH) 2016

Studies from US Oncology Research, The US Oncology Network
and McKesson Specialty Health Affiliated Investigators

San Diego Convention Center, San Diego, CA December 3-6, 2016

Oral Presentations			
Authors	Title	Session #	Date/Time
Lihua E. Budde, Ahmad Halwani, Christopher A. Yasenchak , Charles Michael Farber , John M. Burke , Luis E. Fayad, Beata Holkova, Mark Knapp, Kathryn S. Kolibaba , Ranjana H. Advani, Stephen M. Ansell, Dipti Patel-Donnelly , Habte A. Yimer , Scott E. Smith, Moshe Yair Levy , Mahesh Seetharam , David Belada, Donald Brooks , Edwin C. Kingsley , Leonard M. Klein , Nina Wagner-Johnston, Katherine Ruffner, and Nancy L Bartlett.	Results of an Ongoing Phase 2 Study of Brentuximab Vedotin with Rchp As Frontline Therapy in Patients with High-Intermediate/High-Risk Diffuse Large B Cell Lymphoma (DLBCL)	627 Abstract #104 USOR #13056	Saturday, Dec. 3, 9:30 AM to 11 AM
Jonathan J. Keats, Gil Speyer, Austin Christofferson, Christophe Legendre, Jessica Aldrich, Megan Russell, Lori Cuyugan, Jonathan Adkins, Alex Blanski, Meghan Hodges, Dan Rohrer, Sundar Jagannath, Ravi Vij, Gregory Orloff, Todd Zimmerman, Ruben Niesvizky, Darla Liles, Joseph W. Fay, Jeffrey L. Wolf, Robert M. Rifkin , Norma C. Gutierrez, Jennifer Yesil, Mary Derome, Seungchan Kim, Winnie Liang, Pamela G. Kidd, Scott Jewell, John David Carpten, Daniel Auclair, and Sagar Lonial.	Molecular Predictors of Outcome and Drug Response in Multiple Myeloma: An Interim Analysis of the Mmrf CoMMpass Study	651 Abstract #194 USOR #11152	Saturday, Dec. 3, 2 PM to 3:30 PM
Susan M. O'Brien, Richard R. Furman, Steven E. Coutre, Ian W. Flinn, Jan Burger, Kristie Blum, Jeffrey P. Sharman , William G. Wierda, Jeffrey Jones, Weiqiang Zhao, Nyla A. Heerema, Amy J. Johnson, Ying Luan, Danelle F. James, Alvina D. Chu, and John C. Byrd.	Five-Year Experience with Single-Agent Ibrutinib in Patients with Previously Untreated and Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia	642 Abstract #233 USOR #10086	Saturday, Dec. 3, 4 PM to 5:30 PM

Bolded text: US Oncology Research affiliated investigator

Oral Presentations

Authors	Title	Session #	Date/Time
Umberto Vitolo, Marek Trněný, David Belada, Angelo M. Carella, Neil Chua, Pau Abrisqueta, Judit Demeter, Ian W. Flinn, Xiaonan Hong, Won Seog Kim, Antonio Pinto, John M. Burke , Yuankai Shi, Yoichi Tatsumi, Mikkel Oestergaard, Michael K. Wenger, Günter Fingerle-Rowson, Olivier Catalani, Tina Nielsen, Maurizio Martelli, and Laurie H. Sehn.	Obinutuzumab or Rituximab Plus CHOP in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma: Final Results from an Open-Label, Randomized Phase 3 Study (GOYA)	626 Abstract #470 USOR #12208	Sunday, Dec. 4, 4:30 PM to 6 PM
Rafat Abonour, Brian G.M. Durie, Sundar Jagannath, Jatin J. Shah, Mohit Narang , Howard R. Terebelo, Cristina J. Gasparetto, Kathleen Toomey, James W. Hardin, Amani Kitali, Craig Gibson, Shankar Srinivasan, Arlene S. Swern, and Robert M. Rifkin .	Health-Related Quality of Life of Patients with Newly Diagnosed Multiple Myeloma Receiving Any or Lenalidomide Maintenance after Autologous Stem Cell Transplant in the Connect® MM Disease Registry	904 Abstract #537 USOR #9141	Sunday, Dec. 4, 5 PM
Guillermo Garcia-Manero, Michael R. Savona, Steven D. Gore, Bart L. Scott, Christopher R. Cogle, Thomas Boyd , Paul Conkling , Joel Hetzer, Qian Dong, Keshava Kumar, Stacey M. Ukrainskyj, and Barry S. Skikne.	CC-486 (Oral Azacitidine) in Patients with Hematological Malignancies Who Had Received Prior Treatment with Injectable Hypomethylating Agents (HMAs): Results from Phase 1/2 CC-486 Studies	616 Abstract #905 USOR #12103 #08061 #11197	Monday, Dec. 5, 2:45 PM to 4:15 PM

Poster Presentations

Authors	Title	Session #	Date/Time
David J. Andorsky , Abdulraheem Yacoub, Jacob D. Bitran, Jason Melear , Heather D. Brooks , Kenneth A. Foon, Syed Rizvi, Mary Llorente, Jiahui Li, and Jeffrey P. Sharman .	MAGNIFY: Phase IIIb Randomized Study of Lenalidomide Plus Rituximab (R2) Followed By Lenalidomide Vs. Rituximab Maintenance in Subjects with Relapsed/Refractory Follicular, Marginal Zone, or Mantle Cell Lymphoma	623 Abstract #1798 USOR #13064	Saturday, Dec. 3, 5:30 PM to 7:30 PM
Hervé Tilly, Franck Morschhauser, Nancy L. Bartlett, Jeffrey P. Sharman , Corinne Haioun, Kathryn S. Kolibaba , Andy Chen, Thierry Lamy, Surai Jones, Elicia Penuel, Calvin Lee, and Gilles A. Salles.	Polatuzumab Vedotin Combined with Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) for Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Updated Results of a Phase Ib/II Study	626 Abstract #1853 USOR #13143	Saturday, Dec. 3, 5:30 PM to 7:30 PM
Andres Forero-Torres, Kathryn S. Kolibaba , Thierry Lamy, Surai Jones, Calvin Lee, and Jeffrey P. Sharman .	Polatuzumab Vedotin Combined with Obinutuzumab, Cyclophosphamide, Doxorubicin, and Prednisone (G-CHP) for Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Preliminary Results of a Phase Ib/II Dose-Escalation Study	626 Abstract #1856 USOR #13143	Saturday, Dec. 3, 5:30 PM to 7:30 PM

Bolded text: US Oncology Research affiliated investigator

Poster Presentations

Authors	Title	Session #	Date/Time
Jesus G. Berdeja, Robert M. Rifkin , Roger Lyons , Hui Yang, Anita Zahlten-Kuemeli, Sanjay K. Aggarwa, Karim Iskander, and James Berenson.	Once-Weekly Carfilzomib with Dexamethasone Demonstrated Promising Safety and Efficacy in Patients with Relapsed or Refractory Multiple Myeloma Regardless of Age and Prior Bortezomib Exposure	653 Abstract #2129 USOR #12054	Saturday, Dec. 3, 5:30 PM to 7:30 PM
Jeffrey P. Sharman , Kathryn S. Kolibaba , Andrei R. Shustov, Thomas A. Giever , Leonard M. Klein , Derek Nay, Thomas A. Rado, Alfred Saleh, Danjie Zhang, Wen Shi, Andres Forero, and Sarit Assouline.	Results of a Phase 2 Trial Evaluating Efficacy and Safety of Entospletinib (GS-9973) in Patients with Mantle Cell Lymphoma	623 Abstract #2963 USOR #12154	Sunday, Dec. 4, 6 PM to 8 PM
Jeffrey P. Sharman , Andrei R. Shustov, Mitchell Smith, Christopher T. Hagenstad, Kathryn S. Kolibaba , Esteban Abella-Dominicis, Danjie Zhang, Siddhartha Mitra, Christopher A. Yasenchak , and Farrukh T. Awan.	Updated Results on the Clinical Activity of Entospletinib (GS-9973), a Selective Syk Inhibitor, in Patients with CLL Previously Treated with an Inhibitor of the B-Cell Receptor Signaling Pathway	642 Abstract #3225 USOR #12154	Sunday, Dec. 4, 6 PM to 8 PM
Inhye E. Ahn, Charles Michael Farber, Matthew Davids, David L. Grinblatt, Nicole Lamanna, Anthony R. Mato, Chadi Nabhan, Pavel Kiselev, Arlene S. Swern, E. Dawn Flick, Shriya Bhushan, Kristen Sullivan, Jeffrey P. Sharman , and Christopher R. Flowers.	Early Progression of Disease (< 2 Years) Is a Negative Predictor of Survival in Patients (Pts) with Chronic Lymphocytic Leukemia (CLL): An Analysis from the Connect® CLL Registry	902 Abstract #3581 USOR #10034	Sunday, Dec. 4, 6 PM to 8 PM
Laurie H Sehn, Michael Hallek, Wojciech Jurczak, Jennifer R. Brown, Paul M. Barr, John Catalano, Steven E. Coutre, Richard R. Furman, Nicole Lamanna, Ysebaert Loïc, Andrew D. Zelenetz, Jeffrey P. Sharman , Sven DeVos, Adeboye Henry Adewoye, Yeonhee Kim, Ian W. Flinn, and Gilles A. Salles.	A Retrospective Analysis of Pneumocystis Jirovecii Pneumonia Infection in Patients Receiving Idelalisib in Clinical Trials	203 Abstract #3705 USOR #13141 #13142	Monday, Dec. 5, 6 PM to 8 PM
John M. Burke , Jenny L. Black-Shinn, Jamiya Clark, Jennifer Frytak, Janet Espirito, and Jeffrey P. Sharman .	Management of Elderly Patients with Diffuse Large B-Cell Lymphoma in a Network of Community Oncology Practices in the United States	627 Abstract #4215 HEOR Project	Monday, Dec. 5, 6 PM to 8 PM
Robert M. Rifkin , Rafat Abonour, Brian G.M. Durie, Cristina J. Gasparetto, Sundar Jagannath, Mohit Narang , Jatin J. Shah, Howard R. Terebelo, Kathleen Toomey, Amani Kitali, Faiza Zafar, Shankar Srinivasan, and James W. Hardin.	Treatment Patterns from 2009 to 2015 in Patients with Newly Diagnosed Multiple Myeloma in the United States: A Report from the Connect® MM Registry	653 Abstract #4489 USOR #9141	Monday, Dec. 5, 6 PM to 8 PM

Bolded text: US Oncology Research affiliated investigator

Learn More Today

To learn more about US Oncology Research, please contact us.

For Pharmaceutical & Biotech customers:

call 866.951.2774, email us at USOncologyResearch@mckesson.com,
or visit www.MckessonSpecialtyHealth.com/PharmaBiotech

For Providers:

call 800.482.6700, email us at msh.providers@mckesson.com,
or visit www.usoncology.com
